247 related articles for article (PubMed ID: 18241960)
1. Genetic diversity-independent neutralization of pandemic viruses (e.g. HIV), potentially pandemic (e.g. H5N1 strain of influenza) and carcinogenic (e.g. HBV and HCV) viruses and possible agents of bioterrorism (variola) by enveloped virus neutralizing compounds (EVNCs).
Kotwal GJ
Vaccine; 2008 Jun; 26(24):3055-8. PubMed ID: 18241960
[TBL] [Abstract][Full Text] [Related]
2. Current status and progress of prepandemic and pandemic influenza vaccine development.
Leroux-Roels I; Leroux-Roels G
Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
[TBL] [Abstract][Full Text] [Related]
3. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
[TBL] [Abstract][Full Text] [Related]
4. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
Crevar CJ; Ross TM
Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
[TBL] [Abstract][Full Text] [Related]
5. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.
Kreijtz JH; Bodewes R; van den Brand JM; de Mutsert G; Baas C; van Amerongen G; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
Vaccine; 2009 Aug; 27(36):4983-9. PubMed ID: 19538996
[TBL] [Abstract][Full Text] [Related]
6. Pandemic preparedness: toward a universal influenza vaccine.
Roose K; Fiers W; Saelens X
Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
8. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
[TBL] [Abstract][Full Text] [Related]
9. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
10. 2-deoxy-D-glucose as a potential drug against fusogenic viruses including HIV.
Parris GE
Med Hypotheses; 2008; 70(4):776-82. PubMed ID: 17920779
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.
Patel A; Tran K; Gray M; Li Y; Ao Z; Yao X; Kobasa D; Kobinger GP
Vaccine; 2009 May; 27(23):3083-9. PubMed ID: 19428922
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent effects of pomegranate juice and pomegranate polyphenols on foodborne viral reduction.
Su X; Sangster MY; D'Souza DH
Foodborne Pathog Dis; 2011 Nov; 8(11):1177-83. PubMed ID: 21777065
[TBL] [Abstract][Full Text] [Related]
14. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.
Park KS; Lee J; Ahn SS; Byun YH; Seong BL; Baek YH; Song MS; Choi YK; Na YJ; Hwang I; Sung YC; Lee CG
Virology; 2009 Dec; 395(2):182-9. PubMed ID: 19836045
[TBL] [Abstract][Full Text] [Related]
15. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.
Leroux-Roels G
Expert Opin Biol Ther; 2009 Aug; 9(8):1057-71. PubMed ID: 19555313
[TBL] [Abstract][Full Text] [Related]
16. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
[TBL] [Abstract][Full Text] [Related]
17. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
[TBL] [Abstract][Full Text] [Related]
18. Retroviruses and other latent viruses: the deadliest of pathogens are not necessarily the best candidates for bioterrorism.
Salgado CD; Kilby JM
J S C Med Assoc; 2009 Jun; 105(3):104-6. PubMed ID: 19639767
[TBL] [Abstract][Full Text] [Related]
19. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
Collin N; de Radiguès X;
Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
[TBL] [Abstract][Full Text] [Related]
20. Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic?
Pappaioanou M
Comp Immunol Microbiol Infect Dis; 2009 Jul; 32(4):287-300. PubMed ID: 19318178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
